



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on October 19, 2006
Alicia Falkenbach
Name Alicia Falkenbach
Signature
October 19, 2006
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ansorge, et al.

Filed: January 4, 2006

Serial No.: 10/563,498

For: Use of DPIV and APN Inhibitors for the Treatment of Dermatological Diseases Involving the Hyperproliferation and Modified Differentiation Conditions of Fibroblasts

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicant wishes to make of record the following references under the provisions of 37 CFR §1.97.

U.S. Pat. No. 5,939,560
U.S. Pat. No. 6,573,096

References Cited

Please see attached Form PTO/SB/08 for list of PCT patent applications, foreign patent applications and publications. Legible copies of all applications and publications listed are enclosed.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventors, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)).

Respectfully submitted,

By:

John D. Lopinski, Reg. No. 50,846

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Telephone: (716) 848-1430
Date: October 19, 2006

Please type a plus sign inside this box +

OCT 23 2006

PTO/SB/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/563,498
Filing Date	January 4, 2006
First Named Inventor	Ansorge et al.
Art Unit	
Examiner Name	
Attorney Docket Number	013183.00055

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,939,560	08-17-1999	Jenkins et al.	
	2	US-6,573,096 B1	06-03-2003	Chen	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	1	DE 100 25 464	12-06-2001	Inst Medizintechnologie Magdeb		
	2	DE 101 55 093				
	3	WO 95/15309	06-08-1995	Ferring B.V.		
	4	WO 95/34538	12-12-1995	Universitaire Instelling Antwerpen		
	5	WO 01/54707	08-02-2001	Meltec Multi- Epitope-Ligand- Technologies GmbH		
	6	WO 02/053170	07-11-2002	Ansorge et al.		
	7	WO 2003/045228	06-05-2003	Brigham & Womens Hospital		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/563,498
				Filing Date	January 4, 2006
				First Named Inventor	Ansorge et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	013183.00055

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	GHERSI, et al.; "Regulation of Fibroblast Migration on Collagenous Matrix by a Cell Surface Peptidase Complex"; The Journal of Biological Chemistry; Vol. 277, No. 32, Issue of August 9, 2002; pp. 29231-29241.	
	2	CHUNG, et al.; "Bestatin Analog from Streptomyces Neyagawaensis SL-387"; 2000:141613 CAPLUS; Bioscience, Biotechnology, and Biochemistry (1996); 60(5); 898-900 (Chemical Abstract No. 132:148871).	
	3	FUJII, et al.; "Inhibition of Tumor Cell Invasion and Matrix Degradation by Aminopeptidase Inhibitors"; CAPLUS; Biological & Pharmaceutical Bulletin (1996); 19(1); 6-10 (Chemical Abstract No. 124:193562).	
	4	TOSHIYUKI; "Purification and Characterization of Antisera to Aminopeptidase M & Dipeptidylpeptidase IV, and Their Application to Fibroblast and Fibroblastic Tumors"; 890194970 JICST-EPlus; Journal of the Yonago Medical Association (1989); Vol. 40, No. 1; pp. 10-21.	
	5	RAYNAUD, et al.; "Characterization of Specific Proteases Associated with the Surface of Human Skin Fibroblasts and Their Modulation in Pathology"; Journal of Cellular Physiology, Vol. 151, No. 2, 1992, page 378-385, XP009040761 ISSN: 0021-9541.	
	6	FUJII, et al.; "Inhibition of Tumor Cell Invasion and Matrix Degradation by Aminopeptidase Inhibitors"; Biological and Pharmaceutical Bulletin, Vol. 19, No. 1, 1996, pages 6-10; XP001204025 ISSN: 0918-6158.	
	7	DIMON-GADAL, et al.; "MAP Kinase Abnormalities in Hyperproliferative Cultured Fibroblasts from Psoriatic Skin"; Journal of Investigative Dermatology, Vol. 110, No. 6, June 1998 (1998-06); pages 872-879; XP002308341 ISSN: 0022-202X.	
	8	SAISON, et al.; "Identification of Cell Surface DI Peptidyl Peptidase IV EC-3.4.14.5 in Human Fibroblasts"; Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, 1983; XP002308342 Database accession no. PREV198477050630.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.